Mahamaya Lifesciences Ltd

Mahamaya Lifesciences Ltd reported its audited financial results for FY26, with revenue from operations increasing by 24.5% YoY to ₹32,887.30 Lakhs. EBITDA rose to ₹3,425.88 Lakhs, a 32.06% increase from FY25. Despite accounting and listing-related adjustments impacting profitability, the company achieved a PAT of ₹1,652.33 Lakhs. In H2 FY26, revenue from operations reached ₹16,580.93 Lakhs, with an improved EBITDA margin of 10.79%. The company focuses on expanding its sustainable crop care portfolio and strengthening its market presence.

Mahamaya Lifesciences Ltd has announced its audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. The announcement was made following a Board of Directors meeting held on May 25, 2026, where the results and audit reports were considered and approved. The audit was conducted by N NARESH & CO, Chartered Accountants. The consolidated financial results include the results of its subsidiary M/s. Mahamaya Lifesciences (FZE).

Mahamaya Lifesciences Ltd has announced its audited standalone and consolidated financial results along with the auditor's report for the half year and financial year ended March 31, 2026. The announcement was made pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, following a Board of Directors meeting held on May 25, 2026. The results include the financials of its subsidiary, Mahamaya Lifesciences (FZE) based in UAE.

Mahamaya Lifesciences Ltd has scheduled a Board of Directors meeting on May 25, 2026, to consider and approve the audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026, along with the audit reports. The trading window remains closed until 48 hours after the declaration of the financial results, as per the company's Insider Trading Code and SEBI regulations.

Mahamaya Lifesciences Ltd submitted a Monitoring Agency Report for the half year ended March 31, 2026, as required under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, issued by Infomerics Valuation and Rating Limited, covers the period from November 18, 2025, to March 31, 2026, and pertains to the utilization of proceeds raised through the company's Initial Public Offer (IPO). The company has also approved rescheduling of utilization of the unutilised IPO proceeds in subsequent fiscal years up to March 31, 2028.

Mahamaya Lifesciences Ltd has been awarded the "Great Place to Work" certification, valid from April 2026 to April 2027. This recognition was achieved in the "Under 100 Employees" category, signifying a positive workplace culture and potentially enhancing the company's employer brand.

Mahamaya Lifesciences Ltd. has disclosed under Regulation 31(4) of SEBI (SAST) Regulation, 2011, that the Promoter and Promoter Group have not created any encumbrance on their shares during the financial year ended 31% March 2026. This declaration confirms that no shares, directly or indirectly, were encumbered by the members of the Promoter, Promoter group, or persons acting in concert during the aforementioned financial year.

Mahamaya Lifesciences Ltd. has announced that the trading window will be closed for all insiders, designated persons, and their immediate relatives as covered under the company's code. The closure will be in effect from April 01, 2026 until the expiry of 48 hours from the date of declaration of the Audited Financial Results for the financial year ending March 31, 2026. This decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct to Regulate, Monitor and Report Trading in Securities of the Company.

Mahamaya Lifesciences Ltd. has announced that its Board of Directors has approved the rescheduling of the utilization of the unutilized IPO proceeds in subsequent fiscal years up to March 31, 2028. The decision was made due to various project execution factors and the need to incorporate enhancements in plant configuration, machinery specifications, and civil and structural components. The company assures that there is no change in the project scope, intended capacity, or overall utilization of IPO proceeds.

Mahamaya Lifesciences Ltd, in a recent announcement, has informed the stock exchange about its withdrawal from the Arihant Capital Bharat Connect Virtual Conference Rising Star 2026. The company had previously announced its participation in the conference, which was scheduled for Monday, 9th March, 2026. However, due to internal scheduling constraints and ongoing business priorities, the company has decided to withdraw its participation.